Idecabtagen vicleucel (2) – Abecma®
Multiple myeloma, at least 3 previous therapies
Characteristics
| Start date | 01.03.2024 |
|---|---|
| Resolution | 02.05.2024 |
| INN | Idecabtagen vicleucel |
| Brand name | Abecma® |
| Pharm. company | Bristol-Myers Squibb GmbH & Co. KGaA |
| G-BA Procedure ID | D-1043 |
| Therapeutic area | Oncological diseases Multiple myeloma (MM) Orphan (turnover limit) |
| Reason for procedure |
not completed: discontinued
–
Orphan turnover exceeded
Original resolution: Idecabtagen vicleucel (1) (16.06.2022) |
Associated procedures
| Idecabtagen vicleucel (3) | Abecma® | Bristol-Myers Squibb GmbH & Co. KGaA | Multiple myeloma, at least 2 prior therapies | 4,900–5,250 | 100% additional benefit not proven Orphan (turnover limit) | |
| Idecabtagen vicleucel (2) | Abecma® | Bristol-Myers Squibb GmbH & Co. KGaA | Multiple myeloma, at least 3 previous therapies | n.d. | discontinued Orphan (turnover limit) | |
| Idecabtagen vicleucel (1) | Abecma® | Bristol-Myers Squibb GmbH & Co KGaA | Multiple myeloma (MM), at least 3 previous therapies |
0
1,200–1,300 |
100% Hint for non-quantifiable additional benefit Orphan repealed |
<< List of all resolutions